Deutsche Bank Reiterates Ratings, Price Targets On Several Pharma Firms
In a note out today, Deutsche Bank reiterated a buy rating and $97 price target on Botox maker Allergan (NYSE: AGN), implying substantial upside from where the shares currently trade.
The bank also reiterated a hold and $33 price target on Forest Labs (NYSE: FRX). Deutsche Bank also reiterated buy ratings on Teva (Nasdaq: TEVA) and Medicis Pharmaceutical (NYSE: MRX) with price targets of $46 and $44, respectively.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.